



OPEN ACCESS

EDITED AND REVIEWED BY
Maarten Fokke Bijlsma,
Academic Medical Center, Netherlands

*CORRESPONDENCE

Hemant M. Kocher

✉ h.kocher@qmul.ac.uk

Jesmond Dalli

✉ j.dalli@qmul.ac.uk

†These authors have contributed equally to this work

RECEIVED 11 December 2023

ACCEPTED 16 January 2024

PUBLISHED 24 January 2024

CITATION

Aguirre GA, Goulart MR, Bank BPT, Dalli J and Kocher HM (2024) Corrigendum: Arachidonate 15-lipoxygenase-mediated production of Resolvin D5_{n-3} DPA abrogates pancreatic stellate cell-induced cancer cell invasion. *Front. Immunol.* 15:1353835. doi: 10.3389/fimmu.2024.1353835

COPYRIGHT

© 2024 Aguirre, Goulart, Bank, Dalli and Kocher. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Arachidonate 15-lipoxygenase-mediated production of Resolvin D5_{n-3} DPA abrogates pancreatic stellate cell-induced cancer cell invasion

Gabriel A. Aguirre ¹, Michelle R. Goulart ¹, Barts Pancreas Tissue Bank¹, Jesmond Dalli ^{2*†} and Hemant M. Kocher ^{1*†}

¹Centre for Tumour Biology, Barts Cancer Institute, London, United Kingdom, ²William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, John Vane Science Centre, Queen Mary University of London, London, United Kingdom

KEYWORDS

pancreatic ductal adenocarcinoma, specialized pro-resolving mediator, lipid mediator, cancer-associated fibroblast, all-*trans* retinoic acid, ALOX15, CAF subtypes

A Corrigendum on

Arachidonate 15-lipoxygenase-mediated production of Resolvin D5_{n-3} DPA abrogates pancreatic stellate cell-induced cancer cell invasion

by Aguirre GA, Goulart MR, Barts Pancreas Tissue Bank, Dalli J and Kocher HM (2023) *Front. Immunol.* 14:1248547. doi: 10.3389/fimmu.2023.1248547

In the published article, there was an error in the Supplementary Material: Supplementary Methods, Page 7, at the sentence: “Identification was conducted using published criteria, briefly a minimum of six diagnostic ions in total ion count EPI spectrum, matching retention time to synthetic or authentic standards, MRM peaks with more than five data points, a signal-to-noise ratio > 3 (**Supplementary Figure 2**). [41]. The correct material statement appears below.

“Identification was conducted using published criteria, matching retention time to synthetic or authentic standards, MRM peaks with more than five data points, a signal-to-noise ratio > 3 (**UK/MAP**). In a subset of samples the identity of these mediators was further confirmed by matching a minimum of six diagnostic ions in total ion count EPI spectrum to that of a reference standard (**Supplementary Figure 2**). [41]”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.